Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : The Trump Presidency -- Ignore unavailable to you. Want to Upgrade?

To: Cautious_Optimist who wrote (225209)	2/7/2022 4:04:03 PM
From: bentway	Respond to of 362069

>>than small invitro studies<< Not only that, those 'studies' used 'doses' of Ivermectin orders of magnitude larger than what would be given to a human, or even an animal test subject. As documented here: marketwatch.com Some researchers had immediately disregarded the study, despite its being well-designed, based on the dosing. ..“I saw that when it came out, and I did the mathematical calculation of, is this a drug level you can achieve?” Boulware told me. “I quickly realized, no, this is 50 to 100 times higher than you’d ever get in a human. It took me about 15 minutes to figure out that this was not going to be useful as an antiviral. I set it aside and moved onwards.” There was little interest in ivermectin in the U.S. in those days, though the FDA began warning people that same month not to self-medicate with ivermectin formulations intended for animals. Ivermectin is considered a very good and safe treatment for parasitic worms that can cause diseases in people like river blindness, and is also used to treat worms in livestock and pets. In the spring and summer of 2020, much of the nation’s focus was on three other therapies: hydroxychloroquine, a drug that received emergency-use authorization as a COVID-19 treatment in March 2020; convalescent plasma, which received an EUA of its own in August 2020; and Gilead Sciences’ GILD, -0.22% remdesivir, an antiviral that was eventually approved by the FDA and is now considered part of the standard of COVID-19 care for very sick patients...

To: Cautious_Optimist who wrote (225209)	2/7/2022 4:34:31 PM
From: i-node	Read Replies (1) \| Respond to of 362069

Actually, antibiotics AND vitamins are critical in the treatment of Covid. Essentially every treatment regime gives Azrithromycin with whatever other drugs are called for in an effort to kill off any secondary infection that develops. And Vit C/D are just basic immune system maintenance. >> In health science, as with other "cures" we need more than small invitro studies to be convinced it is helpful and not harmful to humans as with fake Covid cure hydroxychloroquine for example. What we NEED are studies that consider the previous studies in the context of the one being conducted. IF you see success using HCQ in NON-HOSPITALIZED patients but no study using HOSPITALIZED patients has shown success. you try to get NON-HOSPITALIZED participants. You don't keep studying hospitalized patients when you know it is too late. By Q2-Q3 in 2020, we knew that HCQ given in a hospital setting DID NOT WORK. But we also knew that when given in the first five or six days of symptoms it was amazingly effective with a certain drug combination. For some [odd] reason, almost every studied varied from the regime that had shown significant promise. Why is that?